Amryt Pharma Holdings Ltd
LSE:AMYT
Operating Margin
Amryt Pharma Holdings Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
453.2m GBP |
-11%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
756B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
406.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.9B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.7B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.2B USD |
27%
|
Amryt Pharma Holdings Ltd
Glance View
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Amryt Pharma Holdings Ltd's most recent financial statements, the company has Operating Margin of -11.1%.
You don't have any saved screeners yet